![Herbert Loong: Pitfalls of molecular testing in lung and prostate cancers](https://oncodaily.com/pub/uploads/2024/08/Screenshot-2024-08-16-144858-e1723805458430.png)
Herbert Loong: Pitfalls of molecular testing in lung and prostate cancers
Herbert Loong shared on LinkedIn:
“There are many steps required to make Precision Oncology effective, efficient and beneficial to patients. Happy to share the full recording of our recent webinar together with my colleagues Fernando Lopez-Rios and Alicia Morgans where we discuss the journey and pitfalls of molecular testing in lung and prostate cancers. ”
Source: Herbert Loong/LinkedIn
Dr. Herbert H. F. Loong holds several prominent positions in oncology. He is the Chair-Elect of the International Affairs Committee, a Scientific Track Member (2022-2024), and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO).
Additionally, he has been promoted to Steering Committee Member at the Lung Cancer Policy Network. Dr. Loong is also the Chairperson of the Asia Pacific Coalition against Lung Cancer, a Board Member of the Connective Tissue Oncology Society, and a Committee Member of the International Association for the Study of Lung Cancer. He is an Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK).